Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase Ib Dose De-escalation Study With BYL719 in Premenopausal Patients With Locally Advanced or Metastatic Breast Cancer (B-YOND)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02058381
Recruitment Status : Completed
First Posted : February 10, 2014
Last Update Posted : March 9, 2020
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

Brief Summary:
Based on the evidence acquired in the post-menopausal setting with everolimus and on pre-clinical evidences supporting the investigation of PI3K inhibitors, such as alpelisib and buparlisib, in combination with endocrine therapy in hormone receptor-positive MBC, the purpose of this phase Ib trial is to assess the maximum tolerated dose (MTD) and/or the RP2D(s), to characterize the safety and tolerability, to determine the single and multiple dose PK profile and assess the preliminary anti-tumor activity of alpelisib and buparlisib in combination with tamoxifen plus goserelin acetate in premenopausal hormone receptor-positive advanced breast cancer patientsgroup.

Condition or disease Intervention/treatment Phase
Pre-menopausal Breast Cancer PI3K Pathway Inhibition Drug: alpelisib (BYL719) Drug: buparlisib (BKM120) Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase Ib Dose De-escalation Study of the Combination of Tamoxifen Plus Goserelin Acetate With Alpelisib (BYL719) or Buparlisib (BKM120) in Premenopausal Patients With Hormone Receptor-positive/HER2-negative Locally Advanced or Metastatic Breast Cancer
Actual Study Start Date : May 6, 2014
Actual Primary Completion Date : June 19, 2018
Actual Study Completion Date : June 19, 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arm Intervention/treatment
Experimental: Group 1 (alpelisib)
Alpelisib plus Tamoxifen and Goserelin (Group 1)
Drug: alpelisib (BYL719)
BYL 719 350 mg will be administered orally once daily on a continuous dosing schedule starting on day 1 (Group 1 only).

Experimental: Group 2 (buparlisib)
Buparlisib plus Tamoxifen and Goserelin (Group 2)
Drug: buparlisib (BKM120)
BKM120 100 mg will be administered orally once daily on a continuous dosing schedule starting on day 1 (Group 2 only)




Primary Outcome Measures :
  1. Maximum Tolerated Dose (MTD) and/or Recommended Phase II Dose (RP2D) [ Time Frame: 12 months ]
    To estimate the MTD(s) and/or the RP2D(s) of a) alpelisib in combination with tamoxifen plus goserelin acetate (Group 1) and b) buparlisib in combination with Tamoxifen plus goserelin acetate (Group 2) in premenopausal hormone receptor-positive locally advanced or MBC patients.


Secondary Outcome Measures :
  1. Incidence, type, intensity, severity and seriousness of Adverse Events (AEs) during the first 2 cycles dose interruptions, reductions and dose intensity during the study [ Time Frame: 12 months ]
    To characterize the safety and tolerability of a) alpelisib in combination with tamoxifen plus goserelin acetate and b) buparlisib in combination with Tamoxifen plus goserelin acetate

  2. Alpelisib/buparlisib: plasma concentrations and PK parameters, including but not limited to AUC0-t, AUC0-inf, AUC0-24, Cmax, tmax, CL/F, half-life t1/2 and other PK parameters if deemed appropriate. Tamoxifen: trough plasma concentrations [ Time Frame: 12 months ]
    To determine the single and multiple dose PK profile of a) alpelisib in combination with tamoxifen plus goserelin acetate and b) buparlisib in combination with Tamoxifen plus goserelin acetate

  3. Preliminary anti-tumor activity acccording to RECIST 1.1 : It will include overall response rate, clinical benefit, progression free survival and proportion of patients who are alive without progression at 9 months from the date of treatment start [ Time Frame: 12 months ]
    To assess the preliminary anti-tumor activity of a) alpelisib in combination with tamoxifen plus goserelin acetate and b) buparlisib in combination with Tamoxifen plus goserelin acetate

  4. Index score from the EQ-5D-5L; and WPAI-GH scores for work time missed, impairment while working, overall work impairment, and activity impairment [ Time Frame: 12 months ]
    To evaluate and compare the impact of alpelisib and buparlisib in combination with tamoxifen plus goserelin on patient-reported health status and impact on work using the EQ-5D-5L and WPAI-GH questionnaires.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patient has histologically and/or cytologically confirmed diagnosis of breast cancer
  • Patient has radiological or objective evidence of inoperable locally advanced or metastatic breast cancer
  • Patient has HER2-negative breast cancer (based on most recently analyzed tumor sample)
  • Patient has ER positive and/or PgR positive breast cancer by local laboratory testing
  • Patient is premenopausal. Premenopausal status is defined as either:

    1. patient had last menstrual period within the last 12 months, OR
    2. if on tamoxifen within the past 3 months, with a plasma estradiol ≥10 pg/mL and FSH ≤40 IU/l or in the premenopausal range, according to local laboratory definition , OR
    3. in case of chemotherapy induced amenorrhea, with a plasma estradiol ≥10 pg/mL) and/or FSH ≤40 IU/l or in the premenopausal range according to local laboratory definition.
  • Patient has no previous history of endocrine therapy in the metastatic setting.

Note:

  • Patients who received oral endocrine therapy with duration less than 3 weeks or ≤1 injection of LHRH agonist and discontinued for a reason other than suspicious or evidence of disease progression are eligible
  • Adjuvant treatment with tamoxifen monotherapy and LHRH analogue monotherapy is allowed. Patients who received tamoxifen plus LH-RH agonist/antagonist in the adjuvant setting are eligible provided they start investigational treatment at least 12 months after the last dose of tamoxifen or LH-RH agonist/antagonist, whichever came later.
  • Patients who were already established on bisphosphonate therapy may continue on bisphosphonates.

    • Patient has received ≤1 prior chemotherapy line for MBC
    • For patient who received prior systemic therapy, radiological or objective evidence of recurrence or progression on or after the last systemic therapy is needed
    • Patient must have as per RECIST 1.1:
  • measurable disease or
  • non-measurable lytic or mixed (lytic + blastic) bone lesions in the absence of measurable disease.

    • Patient has adequate bone marrow and organ function as defined by the following laboratory values:
    • Patient has an Eastern Cooperative Oncology Group (ECOG) performance status ≦ 2 which the investigator believes is stable at the time of screening.
    • Patient has negative serum pregnancy test (β-hCG) within 72 hrs before starting study treatment.

Exclusion criteria

  • Patient is post-menopausal.
  • Patient has received previous endocrine treatments in the metastatic setting.
  • Patient has received previous treatment with PI3K inhibitors, AKT inhibitors, mTOR inhibitors
  • Patient has received more than one chemotherapy line for metastatic disease
  • Patient has symptomatic CNS metastases
  • Patient who has received wide field radiotherapy ≦ 4 weeks or limited field radiation for palliation ≦ 2 weeks prior to starting study drug or who have not recovered to grade 1 or better from related side effects of such therapy (with exception of alopecia alopecia)
  • Patient has not recovered to grade 1 or better (except alopecia) from related side effects of any prior antineoplastic therapy
  • Patient is currently receiving increasing or chronic treatment (> 5 days) with corticosteroids or another immunosuppressive agent, as chronic administration of corticosteroids (> 5 days) can induce CYP3A4
  • Patient is currently receiving warfarin or other coumarin derived anti-coagulant, for treatment, prophylaxis or otherwise. Therapy with heparin, low molecular weight heparin (LMWH), or fondaparinux is allowed
  • Patient is currently receiving treatment with drugs known to be moderate or strong inhibitors or inducers of isoenzyme CYP3A. The patient must have discontinued strong inducers for at least one week and must have discontinued strong inhibitors before the treatment phase is initiated.
  • Patient has a score ≧ 12 on the PHQ-9 questionnaire
  • Patient selects a response of "1, 2 or 3" to question number 9 on the PHQ-9 questionnaire regarding potential for suicidal thoughts or ideation (independent of the total score of the PHQ-9)
  • Patient has a GAD-7 mood scale score ≧ 15
  • Patient has a medically documented history of or active major depressive episode, bipolar disorder (I or II), obsessive-compulsive disorder, schizophrenia, a history of suicidal attempt or ideation, or homicidal ideation (e.g. risk of doing harm to self or others) or patients with active severe personality disorders (defined according to DSM- IV) are not eligible.
  • Patient has ≧ Common Terminology Criteria for Adverse Events (CTCAE) grade 3 anxiety
  • Patient has active cardiac disease or a history of cardiac dysfunction
  • Patient has a Left Ventricular Ejection Fraction (LVEF) < 50% as determined by Multiple Gated acquisition (MUGA) scan or echocardiogram (ECHO)
  • Patient has any of the following cardiac conduction abnormalities

    1. Ventricular arrhythmias except for benign premature ventricular contractions
    2. Supraventricular and nodal arrhythmias requiring a pacemaker or not controlled with medication
    3. Conduction abnormality requiring a pacemaker
    4. Other cardiac arrhythmia not controlled with medication
    5. Patient has a QTcF > 480 msec on the screening ECG (using the QTcF formula)
  • Patient is currently receiving treatment with medication that has a known risk to prolong the QT interval or inducing Torsades de Pointes, and the treatment cannot be discontinued or switched to a different medication prior to treatment start.
  • Patient has chronic pulmonary disease including dyspnea at rest from any cause or with interstitial lung disease.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02058381


Locations
Layout table for location information
Hong Kong
Novartis Investigative Site
Hong Kong, Hong Kong
Korea, Republic of
Novartis Investigative Site
Seongnam-si, Gyeonggi-do, Korea, Republic of, 13620
Novartis Investigative Site
Gyeonggi-do, Korea, Korea, Republic of, 10408
Novartis Investigative Site
Seoul, Korea, Korea, Republic of, 05505
Novartis Investigative Site
Seoul, Korea, Korea, Republic of, 06351
Novartis Investigative Site
Seoul, Korea, Republic of, 03722
Taiwan
Novartis Investigative Site
Kuei-Shan Chiang, Taoyuan/ Taiwan ROC, Taiwan, 33305
Novartis Investigative Site
New Taipei City, TWN, Taiwan, 23561
Novartis Investigative Site
Kaohsiung City, Taiwan, 83301
Novartis Investigative Site
Taichung, Taiwan, 407
Novartis Investigative Site
Taipei, Taiwan, 10002
Novartis Investigative Site
Taipei, Taiwan, 10449
Novartis Investigative Site
Taipei, Taiwan, 112
Thailand
Novartis Investigative Site
Bangkok, Thailand, 10330
Novartis Investigative Site
Chiang Mai, Thailand, 50200
Sponsors and Collaborators
Novartis Pharmaceuticals
Investigators
Layout table for investigator information
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Novartis Pharmaceuticals
ClinicalTrials.gov Identifier: NCT02058381    
Other Study ID Numbers: CBYL719XIC01
First Posted: February 10, 2014    Key Record Dates
Last Update Posted: March 9, 2020
Last Verified: December 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases